Sipuleucel-T is an FDA-approved autologous DC vaccine in which DCs are incubated ex vivo with a fusion protein of GM-CSF and prostate-specific antigen (PSA) to treat metastatic, castrate-resistant prostate cancer [195]. This evidence concerns the gene KLK3 and prostate cancer.